{"groups":[{"description":"Participants treated with trametinib 0.0125 mg/kg/day","id":"FG000","title":"Part A - TMT 0.0125 mg/kg/Day"},{"description":"Participants treated with trametinib 0.025 mg/kg/day","id":"FG001","title":"Part A - TMT 0.025 mg/kg/Day"},{"description":"Participants under 6 years of age treated with trametinib 0.032 mg/kg/day","id":"FG002","title":"Part A - TMT 0.032 mg/kg/Day"},{"description":"Participants treated with trametinib 0.04 mg/kg/day","id":"FG003","title":"Part A - TMT 0.04 mg/kg/Day"},{"description":"Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day","id":"FG004","title":"Part B - Neuroblastoma"},{"description":"Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day","id":"FG005","title":"Part B - LGG Fusion"},{"description":"Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day","id":"FG006","title":"Part B - NF-1 With PN"},{"description":"Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day","id":"FG007","title":"Part B - BRAF V600 Mutant Solid Tumor"},{"description":"Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for \\<12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)","id":"FG008","title":"Part C - TMT 0.025 mg/kg/Day + 50% DRB RP2D"},{"description":"Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \\<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)","id":"FG009","title":"Part C - TMT 0.025 mg/kg/Day + 100% DRB RP2D"},{"description":"Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)","id":"FG010","title":"Part C - TMT 0.032 mg/kg/Day + 100% DRB RP2D"},{"description":"Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for \\< 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \\<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)","id":"FG011","title":"Part D - LGG"},{"description":"Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for \\< 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \\<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)","id":"FG012","title":"Part D - LCH"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"3"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"3"},{"groupId":"FG012","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"}],"type":"Withdrawal consent"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"}],"type":"Investigator discretion"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"10"},{"groupId":"FG008","numSubjects":"3"},{"groupId":"FG009","numSubjects":"9"},{"groupId":"FG010","numSubjects":"6"},{"groupId":"FG011","numSubjects":"20"},{"groupId":"FG012","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"4"},{"groupId":"FG011","numSubjects":"14"},{"groupId":"FG012","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"13"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"9"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"7"},{"groupId":"FG010","numSubjects":"2"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The participants were screened within 14 days prior to enrollment. After screening, the treatment period started on Cycle 1 Day 1.","recruitmentDetails":"Participants took part in 16 investigative sites in 5 countries."}